Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida. more
Time Frame | OGEN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.52% | 0.49% | -0.42% |
1-Month Return | -6.89% | -3.1% | -2.2% |
3-Month Return | -11.37% | -8.59% | 2.38% |
6-Month Return | -70.93% | -4.57% | 5.1% |
1-Year Return | -94.03% | -0.94% | 23.79% |
3-Year Return | -98.85% | 2.88% | 26.66% |
5-Year Return | -98.81% | 35.84% | 81.16% |
10-Year Return | -99.93% | 98.8% | 191.72% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | 86.99K | 131.52K | 37.65K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":66.14,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":28.63,"profit":true}] |
Cost of Revenue | 62.62K | 51.70K | 41.24K | 44.67K | 15.49M | [{"date":"2019-12-31","value":0.4,"profit":true},{"date":"2020-12-31","value":0.33,"profit":true},{"date":"2021-12-31","value":0.27,"profit":true},{"date":"2022-12-31","value":0.29,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (62.62K) | (51.70K) | 45.75K | 86.85K | (15.45M) | [{"date":"2019-12-31","value":-72.1,"profit":false},{"date":"2020-12-31","value":-59.53,"profit":false},{"date":"2021-12-31","value":52.67,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-17791.87,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | 52.59% | 66.04% | (41040.42%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":79.64,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-62146.56,"profit":false}] |
Operating Expenses | 15.88M | 26.64M | 15.86M | 14.55M | 5.45M | [{"date":"2019-12-31","value":59.6,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":59.52,"profit":true},{"date":"2022-12-31","value":54.62,"profit":true},{"date":"2023-12-31","value":20.46,"profit":true}] |
Operating Income | (15.88M) | (26.64M) | (15.77M) | (14.42M) | (20.90M) | [{"date":"2019-12-31","value":-1587756900,"profit":false},{"date":"2020-12-31","value":-2664145600,"profit":false},{"date":"2021-12-31","value":-1577101800,"profit":false},{"date":"2022-12-31","value":-1441562800,"profit":false},{"date":"2023-12-31","value":-2090490300,"profit":false}] |
Total Non-Operating Income/Expense | 624.28K | 289.37K | 119.50K | 248.04K | 463.75K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":46.35,"profit":true},{"date":"2021-12-31","value":19.14,"profit":true},{"date":"2022-12-31","value":39.73,"profit":true},{"date":"2023-12-31","value":74.29,"profit":true}] |
Pre-Tax Income | (15.57M) | (26.43M) | (15.71M) | (14.29M) | (20.66M) | [{"date":"2019-12-31","value":-1556600300,"profit":false},{"date":"2020-12-31","value":-2643069900,"profit":false},{"date":"2021-12-31","value":-1571161400,"profit":false},{"date":"2022-12-31","value":-1428838900,"profit":false},{"date":"2023-12-31","value":-2065573700,"profit":false}] |
Income Taxes | 7.76K | 12.48K | 16.43K | (127.24K) | (1.00) | [{"date":"2019-12-31","value":47.22,"profit":true},{"date":"2020-12-31","value":75.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-774.62,"profit":false},{"date":"2023-12-31","value":-0.01,"profit":false}] |
Income After Taxes | (15.57M) | (26.44M) | (15.73M) | (14.16M) | (20.66M) | [{"date":"2019-12-31","value":-1557375900,"profit":false},{"date":"2020-12-31","value":-2644317900,"profit":false},{"date":"2021-12-31","value":-1572804000,"profit":false},{"date":"2022-12-31","value":-1416115000,"profit":false},{"date":"2023-12-31","value":-2065573600,"profit":false}] |
Income From Continuous Operations | (15.57M) | (26.43M) | (15.71M) | (14.29M) | (10.15M) | [{"date":"2019-12-31","value":-1556600300,"profit":false},{"date":"2020-12-31","value":-2643069900,"profit":false},{"date":"2021-12-31","value":-1571161400,"profit":false},{"date":"2022-12-31","value":-1428838900,"profit":false},{"date":"2023-12-31","value":-1014604800,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (15.57M) | (26.44M) | (15.73M) | (14.16M) | (20.66M) | [{"date":"2019-12-31","value":-1557375900,"profit":false},{"date":"2020-12-31","value":-2644317900,"profit":false},{"date":"2021-12-31","value":-1572804000,"profit":false},{"date":"2022-12-31","value":-1416115000,"profit":false},{"date":"2023-12-31","value":-2065573700,"profit":false}] |
EPS (Diluted) | (22.20) | (28.80) | (8.40) | (7.71) | (6.65) | [{"date":"2019-12-31","value":-2220,"profit":false},{"date":"2020-12-31","value":-2880,"profit":false},{"date":"2021-12-31","value":-840,"profit":false},{"date":"2022-12-31","value":-771.01,"profit":false},{"date":"2023-12-31","value":-664.87,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
OGEN | |
---|---|
Cash Ratio | 1.48 |
Current Ratio | 1.93 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
OGEN | |
---|---|
ROA (LTM) | -219.89% |
ROE (LTM) | -454.72% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
OGEN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.41 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.59 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
OGEN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 578.50 |
P/B | 2.83 |
Price/FCF | NM |
EV/R | 105.83 |
EV/Ebitda | 0.21 |
PEG | NM |
Oragenics Inc (OGEN) share price today is $0.343
Yes, Indians can buy shares of Oragenics Inc (OGEN) on Vested. To buy Oragenics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OGEN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Oragenics Inc (OGEN) via the Vested app. You can start investing in Oragenics Inc (OGEN) with a minimum investment of $1.
You can invest in shares of Oragenics Inc (OGEN) via Vested in three simple steps:
The 52-week high price of Oragenics Inc (OGEN) is $6.22. The 52-week low price of Oragenics Inc (OGEN) is $0.25.
The price-to-earnings (P/E) ratio of Oragenics Inc (OGEN) is
The price-to-book (P/B) ratio of Oragenics Inc (OGEN) is 2.83
The dividend yield of Oragenics Inc (OGEN) is 0.00%
The market capitalization of Oragenics Inc (OGEN) is $4.32M
The stock symbol (or ticker) of Oragenics Inc is OGEN